NCT06857955

Brief Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

Trial Health

78
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
385

participants targeted

Target at P75+ for phase_2 hypertension

Timeline
22mo left

Started Mar 2025

Typical duration for phase_2 hypertension

Geographic Reach
3 countries

81 active sites

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Mar 2025Apr 2028

First Submitted

Initial submission to the registry

March 3, 2025

Completed
2 days until next milestone

First Posted

Study publicly available on registry

March 5, 2025

Completed
21 days until next milestone

Study Start

First participant enrolled

March 26, 2025

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 29, 2027

Expected
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

April 5, 2028

Last Updated

June 1, 2026

Status Verified

May 1, 2026

Enrollment Period

1.8 years

First QC Date

March 3, 2025

Last Update Submit

May 28, 2026

Conditions

Keywords

QCZ484Hypertension

Outcome Measures

Primary Outcomes (1)

  • Change in Mean 24hr SBP by ABPM

    Change from baseline at Month 3 in mean 24hr systolic blood pressure (SBP) by ambulatory blood pressure measurement (ABPM)

    Baseline, Month 3

Secondary Outcomes (5)

  • Change in Mean 24hr SBP by ABPM

    Baseline, Month 6

  • Change in SBP by OBPM

    Baseline, Month 3 and 6

  • Participants achieving SBP<130 mmHg or SBP reduced by ≥10 mmHg by ABPM

    Baseline, Month 3 and 6

  • Change in DBP by ABPM and OBPM

    Baseline, Month 3 and 6

  • Number of participants with AEs

    Up to Month 18

Study Arms (6)

Placebo Control

PLACEBO COMPARATOR

Placebo

Other: Saline

QCZ484 Dose 1

EXPERIMENTAL

QCZ484 Dose 1 solution for injection

Drug: QCZ484

QCZ484 Dose 2

EXPERIMENTAL

QCZ484 Dose 2 solution for injection

Drug: QCZ484

QCZ484 Dose 3

EXPERIMENTAL

QCZ484 Dose 3 solution for injection

Drug: QCZ484

QCZ484 Dose 4

EXPERIMENTAL

QCZ484 Dose 4 solution for injection

Drug: QCZ484

QCZ484 Dose 5

EXPERIMENTAL

QCZ484 Dose 5 solution for injection

Drug: QCZ484

Interventions

SalineOTHER

0.9% sodium chloride saline solution

Placebo Control
QCZ484DRUG

Solution of Injection

QCZ484 Dose 1QCZ484 Dose 2QCZ484 Dose 3QCZ484 Dose 4QCZ484 Dose 5

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent.
  • Males or females aged 18 to 75 years.
  • Diagnosis of hypertension.
  • Hypertension treatment naive or on maximum 2 anti-HTN medications and able to undergo washout for 4 weeks.
  • Mean sitting SBP ≥140 mmHg measured by OBPM and mean 24 hr SBP ≥130 mmHg and \<160 mmHg measured by ABPM.
  • Participants able to understand and comply with study procedures.

You may not qualify if:

  • Known history of secondary hypertension.
  • Orthostatic hypotension.
  • Laboratory parameter assessments outside of range at screening.
  • Evidence of hepatic disease.
  • Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
  • Any history of congestive heart failure.
  • Current or history of intolerance to ACEi and/or ARBs.
  • Clinically significant cardiac arrhythmias, high-grade AV block and third-degree AV block within 6 months prior to screening.
  • Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 12 months prior to screening. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to screening.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (81)

SEC Clinical Research LLC

Andalusia, Alabama, 36420, United States

Location

UAB St Vincents

Birmingham, Alabama, 35211, United States

Location

Longwood Research

Huntsville, Alabama, 35801, United States

Location

The Center for Clinical Trials

Saraland, Alabama, 36571, United States

Location

Elite Clinical Studies

Phoenix, Arizona, 85018, United States

Location

Synexus Clinical Research US Inc

Tucson, Arizona, 85741, United States

Location

NICRs Research Center

Garden Grove, California, 92844, United States

Location

Valiance Clinical Research

Huntington Park, California, 90255, United States

Location

Downtown L A Research Center Inc

Los Angeles, California, 90017, United States

Location

Clinical Trials Research Sacramento

Sacramento, California, 95821-2134, United States

Location

Encompass Clinical Research

Spring Valley, California, 91978-1522, United States

Location

Clinical Research of Brandon LLC

Brandon, Florida, 33511, United States

Location

ALL Medical Research LLC

Cooper City, Florida, 33024, United States

Location

National Research Institute

Hialeah, Florida, 33013, United States

Location

Cen Exel RCA

Hollywood, Florida, 33024, United States

Location

East Coast Institute for Research

Jacksonville, Florida, 32216, United States

Location

Entrust Clinical Research

Miami, Florida, 33176, United States

Location

Inpatient Research Clinical LLC

Miami Lakes, Florida, 33014, United States

Location

Suncoast Clinical Research

New Port Richey, Florida, 34452, United States

Location

Renstar Medical Research

Ocala, Florida, 34471, United States

Location

American Research Centers of FL

Pembroke Pines, Florida, 33027, United States

Location

Cen Exel FCR

Tampa, Florida, 33613, United States

Location

Cardiology Partners Clinical Research Institute

Wellington, Florida, 33449, United States

Location

Centricity Research

Columbus, Georgia, 31904, United States

Location

Javara Research

Fayetteville, Georgia, 30214, United States

Location

Velocity Clinical Research

Savannah, Georgia, 31406, United States

Location

Solaris Clinical Research

Meridian, Idaho, 83646, United States

Location

Cedar Crosse Research Ct

Chicago, Illinois, 60607, United States

Location

Eagle Clinical Research

Chicago, Illinois, 60621, United States

Location

Synexus Clinical Research US

Evansville, Indiana, 47714, United States

Location

Velocity Clin Research Sioux City

Sioux City, Iowa, 51106, United States

Location

Alliance for Multispecialty Research

Wichita, Kansas, 67207, United States

Location

Velocity Clinical Res Baton Rouge

Baton Rouge, Louisiana, 70809, United States

Location

Southern Clin Research Clinic

Zachary, Louisiana, 70791, United States

Location

Ascension Saint Agnes Heart Care

Baltimore, Maryland, 21229, United States

Location

Anderson Medical Research

Ft. Washington, Maryland, 20744, United States

Location

Capitol Cardiology Associates

Lanham, Maryland, 20706, United States

Location

AA Medical Research Center

Flint, Michigan, 48504, United States

Location

Oakland Medical Research Center

Troy, Michigan, 48085, United States

Location

Trinity Health Michigan Heart

Ypsilanti, Michigan, 48197, United States

Location

Synexus Clinical Research US Inc

Richfield, Minnesota, 55432, United States

Location

Healthcare Research Network II LLC

Hazelwood, Missouri, 63042, United States

Location

Jefferson City Medical Group

Jefferson City, Missouri, 65109, United States

Location

Clin Rsrch Consult a JCCT Company

Kansas City, Missouri, 64111, United States

Location

Velocity Clin at Pioneer Heart Inst

Lincoln, Nebraska, 68506, United States

Location

AMR Las Vegas

Las Vegas, Nevada, 89119, United States

Location

CenExel HRI

Berlin, New Jersey, 08009, United States

Location

Velocity Clinical Research

Binghamton, New York, 13905, United States

Location

Novant Health Heart Vas Inst

Charlotte, North Carolina, 28204, United States

Location

Monroe Biomedical Research

Monroe, North Carolina, 28112, United States

Location

Burke Primary Care

Morganton, North Carolina, 28655, United States

Location

Accellacare of Rocky Mount

Rocky Mount, North Carolina, 27804, United States

Location

Accellacare of Salisbury

Salisbury, North Carolina, 28144, United States

Location

CR Services Acquisition US

Columbus, Ohio, 43213, United States

Location

Conrad Clinical Research

Edmond, Oklahoma, 73013, United States

Location

Velocity Clinical Research Medford

Medford, Oregon, 97504, United States

Location

TCV Clinical Studies

Linwood, Pennsylvania, 19061, United States

Location

Velocity Clinical Research

Union, South Carolina, 29379, United States

Location

Clinical Neuroscience Solutions Inc

Memphis, Tennessee, 38119, United States

Location

Velocity Clinical Research Austin

Austin, Texas, 78759, United States

Location

North Hills Medical Research Inc

Bedford, Texas, 76021, United States

Location

Synergy Group Medical LLC

Houston, Texas, 77061, United States

Location

Biopharma Informatic

Katy, Texas, 77479, United States

Location

Synergy Groups Medical LLC

Missouri City, Texas, 77459, United States

Location

Sun Research Institute

San Antonio, Texas, 78205, United States

Location

Clinical Trials of Texas

San Antonio, Texas, 78229, United States

Location

AMR Layton

Layton, Utah, 84041, United States

Location

Manassas Clinical Research Center

Manassas, Virginia, 20110, United States

Location

Dominion Medical Associates

Richmond, Virginia, 23219, United States

Location

Centricity Research Suffolk Fam Med

Suffolk, Virginia, 23435, United States

Location

MultiCare Ins Research Innovation

Puyallup, Washington, 98372, United States

Location

Velocity Clinical Research Spokane

Spokane, Washington, 99218, United States

Location

Novartis Investigative Site

Suita, Osaka, 5650853, Japan

Location

Novartis Investigative Site

Chuo Ku, Tokyo, 103-0027, Japan

Location

Novartis Investigative Site

Chuo Ku, Tokyo, 104-0031, Japan

Location

Novartis Investigative Site

Chuo-ku, Tokyo, 1030027, Japan

Location

Novartis Investigative Site

Shinjuku Ku, Tokyo, 160-0008, Japan

Location

Novartis Investigative Site

Singapore, 119074, Singapore

Location

Novartis Investigative Site

Singapore, 308433, Singapore

Location

Novartis Investigative Site

Singapore, 519466, Singapore

Location

Novartis Investigative Site

Singapore, 529889, Singapore

Location

MeSH Terms

Conditions

Hypertension

Interventions

Sodium Chloride

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

ChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 3, 2025

First Posted

March 5, 2025

Study Start

March 26, 2025

Primary Completion (Estimated)

January 29, 2027

Study Completion (Estimated)

April 5, 2028

Last Updated

June 1, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

Novartis is commited to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Locations